National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
Latest Information Update: 07 Jan 2026
At a glance
- Drugs Berlim 25/20 association (Primary) ; Empagliflozin; Rosuvastatin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors EMS
Most Recent Events
- 08 Dec 2025 Planned End Date changed from 1 Aug 2025 to 1 Sep 2027.
- 08 Dec 2025 Planned primary completion date changed from 1 Apr 2025 to 1 May 2026.
- 15 Feb 2024 Status changed from not yet recruiting to recruiting.